生物制剂治疗对银屑病相关心血管疾病的影响

Effect of biologics on cardiovascular comorbidities of psoriasis

银屑病易伴发心血管疾病,与动脉粥样硬化存在相似的致病机制,都涉及固有免疫的激活和自身反应性T细胞的活化。近年来,越来越多的生物制剂被运用于银屑病的系统治疗中,包括肿瘤坏死因子α、白细胞介素12/23和白细胞介素17A抑制剂,不同生物制剂的疗效、安全性及其对心血管疾病的影响也引起了皮肤科医生的重视。本文对银屑病和动脉粥样硬化共同的免疫机制,以及不同生物制剂对心血管疾病与相关代谢变化的影响进行了概述。

Psoriasis is prone to be accompanied by cardiovascular diseases.Psoriasis and atherosclerosis have similar pathogenesis,involving the activation of innate immunity and autoreactive T cells.In recent years,more and more biological agents have been applied to systemic treatment of psoriasis,including tumor necrosis factor-α,interleukin-12/23 inhibitors and interleukin-17A inhibitors.The efficacy and safety of different biological agents,as well as their impact on cardiovascular diseases,have also attracted the attention of dermatologists.This review summarizes the common immunological pathogenesis of psoriasis and atherosclerosis,as well as the effects of different biological agents on cardiovascular diseases and related metabolic changes.